Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)

Phase Distribution

Ph not_applicable
1
13%
Ph phase_1
1
13%
Ph phase_2
6
75%

Phase Distribution

1

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
6(75.0%)
N/ANon-phased studies
1(12.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(2)
Terminated(1)
Other(5)

Detailed Status

unknown5
Completed2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (12.5%)
Phase 26 (75.0%)
N/A1 (12.5%)

Trials by Status

withdrawn113%
unknown563%
completed225%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer

NCT03113851
completedphase_2

Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer

NCT01341652
unknownphase_1

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

NCT04072900
withdrawnphase_2

A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

NCT02623595
unknownnot_applicable

Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients

NCT03489616
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03113851Phase 2

Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer

Completed
NCT01341652Phase 2

Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer

Completed
NCT04072900Phase 1

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Unknown
NCT02623595Phase 2

A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

Withdrawn
NCT03489616Not Applicable

Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients

Unknown
NCT02466906Phase 2

RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer

Unknown
NCT01983657Phase 2

Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.

Unknown
NCT01806272Phase 2

Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8